Oxurion NV Business Update - Q1 2020

Oxurion NV Business Update - Q1 2020

Progressing Clinical Development of Next Generation Therapies for Diabetic Eye Disease – Beyond anti-VEGF

Total Cash & Investments at €43.8 million as of March 31, 2020
       

       
Highlights

• Positive data from Phase 1 study evaluating THR-687 (Pan-RGD integrin antagonist) for the treatment of Diabetic Macular Edema (DME) announced in January 2020.

        Preparations for planned Phase 2 study with THR-687 in DME on-going.  Study expected to start in H1 2021.

• Phase 2 study with THR-149 in DME is now expected to start H2 2020, or as soon as COVID-19 related safety considerations allow. Preparations progressing as planned.
   
• At the end of March 2020, Oxurion had cash, cash equivalents & investments of €43.8 million.

             

Leuven, Belgium, May 7, 2020 – 17.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company engaged in the development of next generation therapies to treat diabetic eye disease, today issues its business and financial update for the three-months ending March 31, 2020.

Oxurion continues to progress the development of its pipeline of innovative drug candidates for treating Diabetic Macular Edema (DME). Diabetic eye disease, including DME, is a significant global healthcare problem and the major cause of blindness in adults of working-age.

Oxurion’s clinical development pipeline consists of novel products with different, including non-VEGF, modes of action, which potentially give the Company access to a significant share of the large and fast-growing diabetic eye disease market.

Oxurion’s clinical pipeline comprises of  

• THR-149: a potent plasma kallikrein inhibitor completed a Phase 1 multicenter, dose escalation study for the treatment of DME in July 2019.  Positive data showed that THR-149 is well-tolerated and safe with no dose-limiting toxicities or drug-related serious adverse events reported. The data also showed promising efficacy results in relation to Best Corrected Visual Acuity (BCVA) after a single injection and for up to 90 days of follow up.